Opioid Use Disorders
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Braeburn PharmaceuticalsPA - Plymouth Meeting
1 programCAM2038 SC injectionPHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
AlkermesXR-NTX
Braeburn PharmaceuticalsCAM2038 SC injection
Angeles TherapeuticsXR-NTX
Clinical Trials (3)
Total enrollment: 639 patients across 3 trials
Naltrexone in AUD Reward Drinkers
Start: Mar 2022Est. completion: Jul 202860 patients
Phase 4Recruiting
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Start: Dec 2015Est. completion: Nov 2016428 patients
Phase 3Completed
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
Start: Jun 2015Est. completion: May 2019151 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 639 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.